Cyclacel Pharmaceuticals (CYCC) Stock Price, News & Analysis

Company Overview

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Key Stats

• Today's Range: $0.37 to $0.39
• 50-Day Range: $0.32 to $0.83
• 52-Week Range: $0.31 to $4.00
• Volume: 188,962 shs
• Average Volume: 680,618 shs
• Market Capitalization: $2.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Moderate Buy

Cyclacel Pharmaceuticals Stock Analysis - MarketRank™

Cyclacel Pharmaceuticals scored higher than 67% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cyclacel Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Cyclacel Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cyclacel Pharmaceuticals are expected to grow in the coming year, from ($1.95) to ($1.18) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cyclacel Pharmaceuticals is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cyclacel Pharmaceuticals is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cyclacel Pharmaceuticals has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.07% of the float of Cyclacel Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Cyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cyclacel Pharmaceuticals has recently decreased by 64.62%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cyclacel Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Cyclacel Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.07% of the float of Cyclacel Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Cyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cyclacel Pharmaceuticals has recently decreased by 64.62%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 1.59

News Sentiment

Cyclacel Pharmaceuticals has a news sentiment score of 1.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Cyclacel Pharmaceuticals this week, compared to 0 articles on an average week.

Search Interest

3 people have searched for CYCC on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Cyclacel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cyclacel Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.00% of the stock of Cyclacel Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 23.58% of the stock of Cyclacel Pharmaceuticals is held by institutions.

CYCC Stock Analysis - Frequently Asked Questions

How have CYCC shares performed this year?

Cyclacel Pharmaceuticals' stock was trading at $0.3760 at the beginning of the year. Since then, CYCC shares have decreased by 1.4% and is now trading at $0.3709.
View the best growth stocks for 2025 here.

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) posted its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.36. The biotechnology company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.01 million. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative trailing twelve-month return on equity of 1,901.11%.

When did Cyclacel Pharmaceuticals' stock split?

Cyclacel Pharmaceuticals shares reverse split on Monday, December 18th 2023. The 1-15 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Cyclacel Pharmaceuticals?

Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Cyclacel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclacel Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), General Electric (GE), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 1/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CYCC
• CUSIP: N/A
• CIK: 1130166
• Web: www.cyclacel.com
• Phone: (908) 517-7330
• Fax: 866-271-3466
• Employees: 14
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.00
• High Stock Price Target: $11.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +2,881.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($9.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-22,560,000.00
• Net Margins: -18,150.00%
• Pretax Margin: -21,390.54%
• Return on Equity: -1,901.11%
• Return on Assets: -188.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.77
• Quick Ratio: 0.77

Sales & Book Value

• Annual Sales: $74,000.00
• Price / Sales: 31.35
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.57 per share
• Price / Book: 0.65

Miscellaneous

• Outstanding Shares: 6,287,000
• Free Float: 5,784,000
• Market Cap: $2.32 million
• Optionable: Optionable
• Beta: 0.38